Inflammx Therapeutics, Inc.

Biotechnology ResearchFlorida, United States2-10 Employees

Clinical stage company developing an orally administered compound to inhibit the dysregulated NLRP3 Inflammasome pathway of autoinflammation.
 Indications: Diabetic Macular Edema (DME) secondary to Diabetic Retinopathy (DR) and the early (patients still have good vision) Intermediate form of Age Related Macular Degeneration (iAMD).
Phase 2 asset (Xiflam) positive clinical data demonstrated in a P2 Placebo controlled clinical trial in DME in 2025. Patients dosed once a day with Xiflam or Placebo tablets for 6 months. The objective of InflammX technology is disease modification through inhibiting the dysregulated NLRP3 Inflammasome by normalizing pathological prematurely open connexin 43 hemichannels in the cell membrane. These pathologically open Cx43 hemichannels release ATP into the extracellular space which is a signal for assembly of the NLRP3 Inflammasome and release of multiple proinflammatory cytokines. This results in perpetuated autoinflammation in the clinically indicated diseases mentioned above. Xiflam has been shown to close the pathologically open hemichannels preventing pathological  signaling of the NLRP3 and the perpetuation of inflammation. Peer reviewed literature on the inflammasome supports the Cx43 mechanism as an activator of the NLRP3 inflammasome and drugs such as Xiflam being effective in preventing pathological signaling of the NLRP3 Inflammasome.

Sign up for free to view info

Email Format Employee directory